Results 221 to 230 of about 8,424 (263)
Some of the next articles are maybe not open access.
Clinical Pharmacology of Eptifibatide
The American Journal of Cardiology, 1997Activation of receptor function of platelet membrane glycoprotein (GP) IIb-IIIa leads to the binding of fibrinogen and is the final common pathway to platelet aggregation. Platelet aggregates provide the structural basis for coronary thrombosis, a major cause of ischemic heart disease.
David R. Phillips, Robert M. Scarborough
openaire +3 more sources
Eptifibatide-induced thrombocytopenia
Journal of Thrombosis and Thrombolysis, 2007Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical literature. Here we report a case of a 34-
A.J. Conrad Smith +2 more
openaire +3 more sources
Reversible Thrombocytopenia Associated with Eptifibatide
The Annals of Pharmacotherapy, 2002OBJECTIVE: To report a patient who experienced severe, reversible thrombocytopenia after receiving eptifibatide for acute coronary syndrome. CASE SUMMARY: A 61-year-old white man with a past medical history of coronary artery disease, peripheral vascular disease, insulin-dependent diabetes, hypertension, and dyslipidemia was treated with eptifibatide ...
Rebecca F Edwards, Monty Yoder
openaire +3 more sources
Eptifibatide-induced thrombocytopenia and thrombosis
Journal of Thrombosis and Thrombolysis, 2006Glycoprotein (GP) IIb/IIIa inhibitors have been shown to reduce morbidity and mortality in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). With their widespread use, there is a growing body of literature describing adverse outcomes, including severe thrombocytopenia.
Mike Militello +4 more
openaire +2 more sources
Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide
Journal of Cardiovascular Pharmacology, 2021: Patients with percutaneous coronary interventions undergoing procedures often require interruptions in their dual antiplatelet therapy. Periprocedural bridging is considered for patients at high thrombotic risk using intravenous cangrelor, a reversible
Allison N. Yun +4 more
semanticscholar +1 more source
Cardiology in the Young, 2021
Acute stent thrombosis may complicate neonatal arterial duct stenting for reduced pulmonary blood flow. Thrombolytic agents recanalise the clot but may cause bleeding around the vascular sheaths and other sites. Since early thrombus is platelet mediated,
Z. Mumtaz, K. Sivakumar
semanticscholar +1 more source
Acute stent thrombosis may complicate neonatal arterial duct stenting for reduced pulmonary blood flow. Thrombolytic agents recanalise the clot but may cause bleeding around the vascular sheaths and other sites. Since early thrombus is platelet mediated,
Z. Mumtaz, K. Sivakumar
semanticscholar +1 more source
Eptifibatide-Associated Acute, Profound Thrombocytopenia
Annals of Pharmacotherapy, 2005OBJECTIVE: To describe 3 cases of eptifibatide-associated acute, profound thrombocytopenia. CASE SUMMARIES: A 40-year-old black female received eptifibatide 180-μg/kg double bolus followed by a continuous infusion of 2 μg/kg/min for percutaneous coronary intervention (PCI).
James C. Coons +3 more
openaire +2 more sources
Evaluación económica de eptifibatide
Revista Española de Cardiología, 2001Introduccion y objetivos El objetivo de este estudio es realizar una evaluacion economica para Espana del ensayo PURSUIT, un estudio multicentrico y aleatorio sobre el tratamiento de la angina inestable o el infarto sin onda Q con eptifibatide frente a placebo, asi como medir el coste de cada ano de vida ganado en los pacientes tratados con dicho ...
Francisco Antón Botella +1 more
openaire +2 more sources
American Heart Journal, 1999
The primary cause of acute coronary syndromes is the development of a thrombus, a pathologic manifestation of platelet aggregation that occurs as part of the normal process of hemostasis. The discovery that the final common step in platelet aggregation, through the binding of fibrinogen to the activated platelet integrin glycoprotein (GP) IIb/IIIa, has
openaire +2 more sources
The primary cause of acute coronary syndromes is the development of a thrombus, a pathologic manifestation of platelet aggregation that occurs as part of the normal process of hemostasis. The discovery that the final common step in platelet aggregation, through the binding of fibrinogen to the activated platelet integrin glycoprotein (GP) IIb/IIIa, has
openaire +2 more sources
Stroke
Eptifibatide is a glycoprotein IIb/IIIa inhibitor. Its intraarterial (IA) administration as adjunct therapy during mechanical thrombectomy (MT) lacks substantial supportive evidence. Objective: To identify any correlation between IA eptifibatide (135
Abdallah O Amireh +10 more
semanticscholar +1 more source
Eptifibatide is a glycoprotein IIb/IIIa inhibitor. Its intraarterial (IA) administration as adjunct therapy during mechanical thrombectomy (MT) lacks substantial supportive evidence. Objective: To identify any correlation between IA eptifibatide (135
Abdallah O Amireh +10 more
semanticscholar +1 more source